Charles River Laboratories International (NYSE:CRL) EVP Shannon Parisotto Sells 2,156 Shares of Company Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 2,156 shares of Charles River Laboratories International stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total transaction of $742,547.96. Following the completion of the transaction, the executive vice president directly owned 4,807 shares in the company, valued at approximately $1,655,578.87. This trade represents a 30.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Up 1.6%

CRL stock opened at $345.08 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The firm has a market capitalization of $16.47 billion, a P/E ratio of -71.15, a P/E/G ratio of 3.17 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52-week low of $146.20 and a 52-week high of $351.21. The company’s 50 day simple moving average is $294.35 and its 200-day simple moving average is $233.22.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same quarter last year, the business posted $3.12 EPS. The company’s revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.38 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Signaturefd LLC raised its stake in shares of Charles River Laboratories International by 563.5% in the 3rd quarter. Signaturefd LLC now owns 8,865 shares of the medical research company’s stock valued at $2,615,000 after acquiring an additional 7,529 shares in the last quarter. Evergreen Capital Management LLC bought a new stake in Charles River Laboratories International during the third quarter worth approximately $2,621,000. Sterling Capital Management LLC boosted its position in Charles River Laboratories International by 350.3% during the third quarter. Sterling Capital Management LLC now owns 6,642 shares of the medical research company’s stock worth $1,959,000 after purchasing an additional 5,167 shares during the period. Yousif Capital Management LLC boosted its position in Charles River Laboratories International by 721.8% during the third quarter. Yousif Capital Management LLC now owns 43,367 shares of the medical research company’s stock worth $12,794,000 after purchasing an additional 38,090 shares during the period. Finally, Compass Wealth Management LLC acquired a new position in Charles River Laboratories International during the third quarter valued at approximately $69,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

CRL has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised Charles River Laboratories International from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $180.00 to $310.00 in a research report on Thursday, August 6th. UBS Group initiated coverage on Charles River Laboratories International in a research report on Wednesday, September 30th. They set a “buy” rating and a $357.00 price target on the stock. Deutsche Bank Aktiengesellschaft increased their price objective on Charles River Laboratories International from $300.00 to $320.00 and gave the stock a “buy” rating in a research note on Friday, September 25th. CLSA lowered Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a research report on Monday, July 20th. Finally, Zacks Research raised Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $302.33.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.